Joaquin DuatoChairman & Chief Executive Officer, Johnson & Johnson (JNJ)
5 recorded appearances
Interviewed by David Rubenstein, Duato says J&J's focus is on fighting cancer rather than chasing obesity drugs, and defends the company's capital allocation toward oncology and medtech.
With Alan Murray, Duato discusses J&J's oncology breakthroughs, the longevity question, and where AI is genuinely compressing drug-development timelines versus where it is still hype.
With CNBC's Angelica Peebles, Duato sets the goal of J&J becoming the number one oncology company by 2030, and addresses the FDA leadership overhaul, global drug pricing and the 'most favored nation' policy.
Duato argues J&J is entering a phase of accelerated growth as its innovative-medicine pipeline converts, and addresses tariff and pricing pressure on pharma.
Duato discusses J&J's outlook with Jim Cramer, including the effect of President Trump's pharmaceutical tariff policy on where J&J manufactures.